X
[{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Pheno Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pheno Therapeutics Announces Worldwide License From UCB to a Novel Program for Neurodegenerative Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"UCB Pharma S.A"},{"orgOrder":0,"company":"Complix","sponsor":"Jiangsu Nhwa Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Complix Discovery Development Agreement Jiangsu Develop Alphabody Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Complix"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Flanders Innovation & Entrepreneurship","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"Confo Therapeutics Awarded EUR 1M VLAIO Grant for Pre-Clinical Development of CFTX-1554","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"BELGIUM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Confo Therapeutics"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Confo Therapeutics"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
Under the terms of the agreement, Confo will lead the discovery and development of small molecule agonists against an undisclosed target associated with CNS diseases.
Lead Product(s):
Undisclosed
Therapeutic Area: Neurology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Daiichi Sankyo
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
March 30, 2023
Details:
The agreement grants Pheno Therapeutics access and rights to develop, manufacture and commercialize a preclinical-stage program of novel small molecules designed to promote remyelination.
Lead Product(s):
Undisclosed
Therapeutic Area: Neurology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Pheno Therapeutics
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
January 11, 2023
Details:
Under the terms of the agreement, Complix has granted an exclusive license to Nhwa to develop, manufacture and commercialize the CPABs resulting from this collaboration in Greater China.
Lead Product(s):
Alphabody Therapeutics
Therapeutic Area: Neurology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Jiangsu Nhwa Pharmaceutical
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Agreement
July 28, 2021
Details:
The grant covers clinical trial application-enabling studies to further characterize the pharmacology and safety of CFTX-1554 and the development of appropriate manufacturing protocols and translational biomarker studies to examine the mechanism of action of AT2R modulation.
Lead Product(s):
CFTX-1554
Therapeutic Area: Neurology
Product Name: CFTX-1554
Highest Development Status: Discovery
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Flanders Innovation & Entrepreneurship
Deal Size: $1.2 million
Upfront Cash: Undisclosed
Deal Type: Funding
March 30, 2021